Navigation Links
Nile Therapeutics Completes Dosing of Phase II Study
Date:7/7/2010

torical facts, included in this press release regarding the timing, progress and anticipated results of the clinical development, regulatory processes, clinical trial and data analysis timelines, anticipated benefits of CD-NP, Nile's strategy, future operations, outlook, milestones, the timing and success of Nile's product development, future financial position, future financial results, plans and objectives of management are forward-looking statements. Nile may not actually achieve these plans, intentions or expectations and Nile cautions investors not to place undue reliance on Nile's forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements Nile makes. Various important factors that could cause actual results or events to differ materially from the forward-looking statements that Nile makes include Nile's need to raise additional capital to fund its product development programs to completion, Nile's reliance on third-party researchers to develop its product candidates, and its lack of experience in developing and commercializing pharmaceutical products. Additional risks are described in greater detail in the reports Nile files with Securities and Exchange Commission, including those described under the caption "Risk Factors" in Item 1A of its Annual Report on Form 10-K for the year ended December 31, 2009 filed with the Securities and Exchange Commission on March 3, 2010. Nile is providing this information as of the date of this press release and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise.


'/>"/>
SOURCE Nile Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
3. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
10. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
11. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... Oct. 30, 2014   NxStage® Kidney Care, Inc ., ... ), is proud to host the grand opening ceremony of ... 1600 W. 16 th Street on November 20, 2014 ... highly trained medical staff who are committed to providing patients ... life benefits made possible through more flexible dialysis treatment options.   ...
(Date:10/30/2014)... Oct. 30, 2014  Electronic health records uptake ... result of government initiatives and the considerable resources ... have invested over the past five years. Electronic ... IT, and U.S. clinicians use them on a ... http://photos.prnewswire.com/prnh/20141029/155278LOGO Frost & Sullivan,s ...
(Date:10/30/2014)... , Oct. 30, 2014  Nektar Therapeutics (Nasdaq: ... for the third quarter ended September 30, 2014 on ... financial markets. Howard Robin , president and chief ... the results beginning at 5:00 p.m. Eastern Time (ET)/2:00 ... release and a live audio-only Webcast of the conference ...
Breaking Medicine Technology:Grand Opening of NxStage Kidney Care Oak Brook IL Center 2Grand Opening of NxStage Kidney Care Oak Brook IL Center 3Electronic Health Record Usability: CIOs Weigh In 2Electronic Health Record Usability: CIOs Weigh In 3Electronic Health Record Usability: CIOs Weigh In 4Nektar to Announce Financial Results for the Third Quarter 2014 on Thursday, November 6, 2014, After Close of U.S.-Based Financial Markets 2
... WESTON, Fla., Oct. 8 American Scientific Resources Inc. (PINK ... for the periods ending December 31, 2007 and December 31, ... www.Pinksheets.com . ... , is a leading provider of innovative next-generation, health, medical, ...
... , ALEXANDRIA, Va., Oct. 8 The Health Industry ... campaign focused on educating key audiences about the value ... of patient procedures are supported by medical products delivered ... role distributors play in supporting healthcare and making it ...
Cached Medicine Technology:American Scientific Resources Inc. Discloses Audited Financials for 2007 and 2008 2
(Date:10/30/2014)... her research group at the DFG Research Center for ... TU Dresden (CRTD) demonstrated for the first time the ... in three dimensions from mouse embryonic stem cells. Correct ... along the dorsal/ventral axis was observed., This study has ... Stem Cell Reports " on 30.10.2014 ., For many ...
(Date:10/30/2014)... 30, 2014 Timothy, InstaKNOT’s ... Beach firefighters, showing that you are never too young ... met firefighters Tracey and Carl at the 2013 Santa ... the Pompano Beach Chamber of Commerce. Tracey gave Timothy ... letting Timothy wear his real fireman’s hat, and extending ...
(Date:10/30/2014)... Calif. (PRWEB) October 30, 2014 ... mutually exclusive concepts in the medical-grade skin care ... the development of uniquely potent topical dermatological products, ... System ( http://www.RefinitySkinScience.com ) with patented COSMEDERM®-7 anti-irritant ... glycolic acid concentrations (50% and 70%) and a ...
(Date:10/30/2014)... 30, 2014 Paramount Rx, a full-service ... increasing efforts to help people save money through its ... increase for prescription drugs in the new health care ... resources to bridge the relationship between consumers, businesses and ... biggest challenges people face today with medical costs is ...
(Date:10/30/2014)... Tara Haelle HealthDay ... -- More than 100 genes have been identified that ... report. And researchers say they are on their ... may contribute to the disorder. Autism spectrum disorders ... and social difficulties and repetitive behaviors. An estimated one ...
Breaking Medicine News(10 mins):Health News:Reconstruction of a patterned piece of spinal cord in 3-D culture 2Health News:4-year-old InstaKNOT CEO Honors Local Firefighters with Community Support 2Health News:4-year-old InstaKNOT CEO Honors Local Firefighters with Community Support 3Health News:4-year-old InstaKNOT CEO Honors Local Firefighters with Community Support 4Health News:Cosmederm Redefines Peel Science Standard with Launch of Refinity® Skin Health System 2Health News:Cosmederm Redefines Peel Science Standard with Launch of Refinity® Skin Health System 3Health News:Cosmederm Redefines Peel Science Standard with Launch of Refinity® Skin Health System 4Health News:Paramount Rx Discount Card Program Provides Valuable Resources in Midst of Current Health Care Reform 2Health News:Paramount Rx Discount Card Program Provides Valuable Resources in Midst of Current Health Care Reform 3Health News:Discovery of 100-Plus Genes Tied to Autism May Improve Treatments 2Health News:Discovery of 100-Plus Genes Tied to Autism May Improve Treatments 3
... Insurance Coverage Exclusions for Preexisting Conditions WASHINGTON, March ... -- a national, non-profit organization dedicated to the ... to health care through public policy reform at ... Senator Jay Rockefeller (D-WV) and Representative Joe Courtney ...
... Renaissance Laser and Vein Institute, the industry-leading ... patients. The Renaissance Laser and Vein Institute ... plastic and reconstructive surgery.In a faltering economy, many ... pricey beauty rituals to save money. Though this ...
... campaign goalFAIRFAX, Va., March 17 The newly formed ... million as part of its initial campaign goal and ... goal. This includes a recent pledge of $1 million ... high precision radiation therapy treatments for cancer and other ...
... Story" is a riveting 60-second spot depicting a biomedical ... March 17 The Foundation for Biomedical Research (FBR) ... Story." The 60-second spot introduces viewers to a ... cancer research, and is now herself battling this disease ...
... likely to be infected, study finds , , TUESDAY, March 17 ... help decrease the spread of tuberculosis in hospitals, researchers suggest. ... to air from patient rooms in a hospital in Lima, ... The study found that 35 percent of guinea pigs exposed ...
... April 19 SALT LAKE CITY, March 17 Within ... for trained IT professionals who understand healthcare. Western ... established to address workforce needs by offering relevant, accessible ... meet that need by offering a B.S. in ...
Cached Medicine News:Health News:National Patient Advocate Foundation Hails Senator Rockefeller, Representative Courtney for Introducing Preexisting Conditions Bill, Ensuring Patient Access to Health Coverage 2Health News:Renaissance Laser and Vein Clinic (laserandveinclinic.com) Provides Clients with Affordable Varicose Vein Removal Treatment 2Health News:Radiation Oncology Institute (ROI) Campaign Raises $7 Million 2Health News:Foundation for Biomedical Research Releases Groundbreaking PSA 2Health News:Western Governors University Addresses Rising Demand for Healthcare IT Professionals with B.S. in Health Informatics 2Health News:Western Governors University Addresses Rising Demand for Healthcare IT Professionals with B.S. in Health Informatics 3
... procedures are now greatly improved with Volk's ... new lens promotes precise and focused laser ... optimized for enhanced viewing and laser treatment ... design comes standard with LaserWindow for optimal ...
... Super Macula® 2.2 offers extremely high resolution ... while achieving an exceptionally wide 78° field ... choice for critical evaluation of the optic ... detailed views of the macula and disc. ...
... Volk Area Centralis® is excellent for ... and changes from macular degeneration, retinal ... diabetic retinopathy and other retinal conditions. ... treatment of these conditions providing excellent ...
... The original 130° QuadrAspheric lens has ... 1989 as the preferred wide field fundus ... provides a definite advantage over competitive wide ... displacement, and ease of use. This lens ...
Medicine Products: